Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

HitGen Out-Licenses China Rights for Trk/ROS1 Inhibitor to Baiyunshan

publication date: Nov 11, 2020

HitGen of Chengdu out-licensed China rights for its Trk/ROS1 inhibitor to Guangzhou Baiyunshan Pharma. Baiyunshan will pay $6 million upfront and be responsible for milestone and royalty payments, though details were not disclosed. HitGen discovered HG030, a novel second-gen Trk/ROS1 inhibitor, using its DNA-encoded chemical libraries (DELs) platform. In March, China's NMPA approved the company's IND for the inhibitor to treat patients with NTRK/ROS1 gene fusion-positive cancers. More details....

Stock Symbols: (SHA: 688222) (SHA: 600332; HK: 00874)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.